Twist Biosciences shares fell 6.1% after investors reacted negatively, likely due to cautious outlook signals and uneven growth across segments, which overshadowed revenue gains and margin expansion.

• Total revenue increased 19% year-over-year to $110.7 million, marking the 13th consecutive quarter of sequential growth.
• DNA synthesis and Protein Solutions led growth with a 28% increase, driven by AI-enabled drug discovery partnerships like Amazon BioDiscovery.
• Next-generation sequencing (NGS) revenues showed more modest growth of 12% year-over-year and 9% sequentially, reflecting slower momentum in this segment.
• Gross margin expanded above 50%, supporting plans for adjusted EBITDA breakeven by Q4 fiscal 2026.
• Despite positive operational progress, cautious commentary on market adoption and selective customer investment likely tempered investor enthusiasm.